BioCryst Pharmaceuticals Inc (BCRX) Stock Price

BCRXStock

$9.54+15.94%52W

Market Cap$2.44B

P/E9.56x

PEG Ratio9.39

Div yield—

Beta0.56

BCRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)17.11%

Price vs S&P 500 (4W)9.92%

PEG Ratio9.39

VGM Score72.56

P/E Ratio (Annual)9.56x

P/CF (Annual)7.26x

Book Value / Share (Quarterly)$0.19

P/TBV (Annual)15.62x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)47.83%

Cash Flow / Share (Quarterly)$1.52

Price vs S&P 500 (YTD)13.08%

Gross Margin (TTM)97.78%

Net Profit Margin (TTM)-40.90%

EPS (TTM)$-1.50

10-Day Avg Trading Volume2.34M

EPS Excl Extra (TTM)$-1.50

Revenue Growth (5Y)117.92%

EPS (Annual)$1.21

ROI (Annual)-92.13%

Gross Margin (Annual)97.82%

Net Profit Margin (5Y Avg)-53.26%

Cash / Share (Quarterly)$1.38

P/E Basic Excl Extra (TTM)8.33x

Revenue Growth QoQ (YoY)33.61%

P/E Normalized (Annual)9.56x

ROA (Last FY)51.32%

Revenue Growth TTM (YoY)68.72%

EBITD / Share (TTM)$-1.37

ROE (5Y Avg)-820.53%

Operating Margin (TTM)-34.69%

Cash Flow / Share (Annual)$1.62

P/B Ratio75.06x

P/B Ratio (Quarterly)18.05x

Net Income / Employee (Annual)$606,600

EV / Revenue (TTM)3.39x

Net Interest Coverage (TTM)4.91x

ROA (TTM)-77.58%

EPS Growth QoQ (YoY)1179.65%

EV / EBITDA (TTM)9.82x

EPS Incl Extra (Annual)$1.21

Current Ratio (Annual)2.06x

Quick Ratio (Quarterly)2.22x

3-Month Avg Trading Volume4.39M

52-Week Price Return15.94%

EV / Free Cash Flow (Annual)9.25x

P/E Incl Extra (TTM)8.33x

Revenue / Employee (TTM)$2,162,300

Tangible BV / Share (Quarterly)$1.73

P/S Ratio (Annual)2.88x

Asset Turnover (Annual)1.70x

52-Week High$11.22

Operating Margin (5Y Avg)-27.19%

EPS Excl Extra (Annual)$1.21

CapEx CAGR (5Y)37.07%

Tangible BV CAGR (5Y)-18.04%

26-Week Price Return29.04%

Quick Ratio (Annual)1.95x

13-Week Price Return7.91%

Total Debt / Equity (Annual)2.09x

Current Ratio (Quarterly)2.32x

Enterprise Value$3.19B

Revenue / Share Growth (5Y)106.57%

Asset Turnover (TTM)1.90x

Book Value / Share Growth (5Y)-25.06%

Revenue / Employee (Annual)$2,011,100

Inventory Turnover (Annual)2.83x

Pretax Margin (Annual)30.56%

Cash / Share (Annual)$1.29

3-Month Return Std Dev47.34%

Gross Margin (5Y Avg)97.31%

Net Income / Employee (TTM)$-884,300

ROE (Last FY)-284.33%

Net Interest Coverage (Annual)-4.80x

EPS Basic Excl Extra (Annual)$1.21

P/FCF (TTM)5.60x

Receivables Turnover (TTM)9.32x

EV / Free Cash Flow (TTM)8.22x

Total Debt / Equity (Quarterly)2.26x

EPS Incl Extra (TTM)$-1.50

Receivables Turnover (Annual)9.41x

ROI (TTM)-106.66%

P/S Ratio (TTM)2.68x

Pretax Margin (5Y Avg)-52.58%

Revenue / Share (Annual)$4.00

Tangible BV / Share (Annual)$0.72

Forward P/E23.66x

Price vs S&P 500 (52W)-2.62%

P/E Ratio (TTM)8.33x

Year-to-Date Return25.90%

5-Day Price Return1.45%

EPS Normalized (Annual)$1.21

ROA (5Y Avg)-17.37%

Net Profit Margin (Annual)30.16%

Month-to-Date Return9.35%

Cash Flow / Share (TTM)$-1.24

EBITD / Share (Annual)$1.49

Operating Margin (Annual)37.00%

LT Debt / Equity (Annual)1.08x

P/CF (TTM)6.45x

ROI (5Y Avg)-77.15%

P/E Excl Extra (TTM)8.33x

LT Debt / Equity (Quarterly)0.80x

EPS Basic Excl Extra (TTM)$-1.50

P/TBV (Quarterly)4.30x

P/B Ratio (Annual)13.88x

Inventory Turnover (TTM)3.18x

Pretax Margin (TTM)-40.53%

Book Value / Share (Annual)$0.25

Price vs S&P 500 (13W)5.96%

Beta0.56x

P/FCF (Annual)7.31x

Revenue / Share (TTM)$3.55

ROE (TTM)-328.82%

52-Week Low$6.00

vGradeB

gGradeA

mGradeB

vgmGradeB

BCRX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	$0.23	$0.35	+49.40%(+$0.12)
Q1 2026	May 6, 2026	$0.11	$0.14	+27.68%(+$0.03)
Q4 2025	Feb 26, 2026	$0.07	$0.21	+197.57%(+$0.14)
Q3 2025	Nov 3, 2025	$0.07	$0.16	+125.29%(+$0.09)
Q2 2025	Aug 4, 2025	$0.03	$0.04	+47.12%(+$0.01)

BCRX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.25

4.18

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.54
AMGNAmgen Inc	C	C	B	$430.65
GILDGilead Sciences Inc	C	B	B	$146.29
ARGXargenx SE American Depositary Shares	D	A	B	$1019.06
MRNAModerna, Inc. Common Stock	D	C	A	$141.60
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$202.42
BIIBBiogen Inc. Common Stock	C	D	B	$218.07
BNTXBioNTech SE American Depositary Share	C	C	C	$101.63
NBIXNeurocrine Biosciences Inc	C	B	C	$153.63
EXELExelixis Inc	C	B	B	$54.27
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.48
TECHBio-Techne Corp.	D	C	B	$72.31
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$348.08
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$135.03
RGENRepligen Corp	D	C	B	$178.60
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$116.13
QGENQIAGEN N.V.	C	C	B	$43.21
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.54
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$137.87
IBRXImmunityBio, Inc. Common Stock	F	A	B	$7.96
IMVTImmunovant, Inc. Common Stock	—	—	B	$40.23
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$56.82
CGONCG Oncology, Inc. Common stock	F	A	B	$73.84
CRSPCRISPR Therapeutics AG	D	B	C	$56.59
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.24
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$24.32
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$23.60
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$7.87
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$73.41
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$28.79
KODKodiak Sciences Inc Common Stock	—	—	B	$36.96
MESOMesoblast Limited American Depositary Shares	D	B	B	$16.74
ADMAADMA Biologics, Inc.	C	C	C	$9.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.35
VCELVericel Corporation	D	B	B	$39.45
ALVOAlvotech Ordinary Shares	C	D	C	$5.23
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$35.99
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.75
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.58
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$122.92
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.36
NVAXNovavax Inc	B	D	C	$9.61
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.76
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$26.07
REPLReplimune Group, Inc.	—	—	A	$15.20
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.39
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.67
VORVor Biopharma Inc. Common Stock	—	—	B	$22.42
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.66
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	C	$13.51
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	B	$23.93

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals is a biotechnology company developing small-molecule drugs that target key enzymes involved in infectious and inflammatory diseases. The company's clinical and preclinical pipeline addresses acute and seasonal influenza, hereditary angioedema, filoviruses including Ebola and Marburg, and oncology. BioCryst leverages computational biology and medicinal chemistry to advance its targeted therapeutic candidates.